Skip to main content

Table 1 Participants’ characteristics and Ct values at baseline

From: Effect of vitamin D supplementation versus placebo on recovery delay among COVID-19 Tunisian patients: a randomized-controlled clinical trial

 

All participants

Intervention group

(Group A) (n=57)

Control group (Group B) (n=60)

p-value

Participants’ characteristics

 Age (years): mean (SD)

42 (14)

43 (15)

41 (14)

0.58

 Sex (n (%))

  Male

65 (55.6)

33 (50.8)

32 (49.2)

 

  Female

52 (44.4)

24 (46.2)

28 (53.8)

0.62

 Medical history (n (%))

  None

85 (72.6)

36 (42.3)

49 (57.6)

0.06

  Asthma

8 (6.8)

3 (37.5)

5 (62.5)

0.26

  Diabetes millitus

14 (11.9)

7 (50.0)

7 (50.0)

0.81

  Arterial hypertension

8 (6.8)

6 (75.0)

2 (25.0)

0.66

  Others

7 (5.9)

5 (71.4)

2 (28.5)

0.85

 Symptoms (n (%))

  None

77 (65.8)

34 (44.2)

43 (55.8)

0.35

  Otorhinolaryngologic symptomsa

15 (12.8)

7 (46.7)

8 (53.3)

0.85

  Respiratory symptoms b

7 (6.0)

4 (57.1)

3 (42.9)

0.51

  Digestive disordersc

3 (2.6)

1 (33.3)

2 (66.7)

0.71

  General signsd

15 (12.8)

4 (26.7)

11 (73.3)

0.047

Baseline Ct values: mean (SD)

 All

 

29.0

30.0

0.653

 Clinical form

  Symptomatic form

27.7 (12.9)

26.1 (14.2)

29.6 (11.5)

0.421

  Asymptomatic form

30.37 (9.63)

30.7 (9.2)

30 (10.1)

0.787

 Symptoms

  None

30.5 (9.4)

30.8 (9)

30.2 (9.8)

0.805

  Otorhinolaryngological symptomsa

30 (9.3)

26 (13.1)

33.1 (3.5)

0.166

  Respiratory symptomsb

33.6 (2.88)

32.5 (3.5)

34.3 (2.8)

0.565

  General signsd

24.4 (16.3)

24 (16.8)

25.5 (17.2)

0.884

 Medical history

  No

30.3 (9.6)

28.8 (11.2)

31.3 (8.2)

0.322

  Yes

27.3 (13.3)

28.3 (12.5)

26 (14.7)

0.639

  1. CT Cycle threshold, SD Standard deviation
  2. aOtorhinolaryngological symptoms (anosmia, ageusia, flu syndrome, sore throat)
  3. bRespiratory symptoms (cough, dyspnea, chest pain)
  4. cDigestive disorders (diarrhea, vomiting)
  5. dGeneral signs (asthenia, stiffness, myalgia, headache, pain)